Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction
US6251904A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Sep 29, 1999 |
| Grant date | Jun 26, 2001 |
| Priority date | — |
| Expiry date | Sep 29, 2019 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D487/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compounds of the formulae (IA) and (IB): ##STR1## wherein R.sup.1 is C.sub.1 to C.sub.3 alkyl optionally substituted with phenyl, Het or a N-linked heterocyclic group selected from piperidinyl and morpholinyl; wherein said phenyl group is optionally substituted by one or more substitutents selected from C.sub.1 to C.sub.4 alkoxy; halo; CN; CF.sub.3 ; OCF.sub.3 or C.sub.1 to C.sub.4 alkyl wherein said C.sub.1 to C.sub.4 alkyl group is optionally substituted by C.sub.1 to C.sub.4 haloalkyl or haloalkoxy either of which is substituted by one or more halo atoms; R.sup.2 is C.sub.1 to C.sub.6 alkyl and R.sup.13 is OR.sup.3 or NR.sup.5 R.sup.6, or pharmaceutically or veterinarily acceptable salts thereof, or pharmaceutically or veterinarily acceptable solvates of either entity are potent and selective inhibitors of type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterase (cGMP PDE5) and have utility in the treatment of, inter alia, male erectile dysfunction (MED) and female sexual dysfunction (FSD).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.